| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
288 |
| Employees |
346 |
| Revenues (TTM) (Millions $) |
288 |
| Net Income (TTM) (Millions $) |
-74 |
| Cash Flow (TTM) (Millions $) |
296 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Immunogen Inc. is a biotechnology company that specializes in the development of targeted cancer therapies. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Immunogen's core technology is its Antibody Drug Conjugate (ADC) technology, which involves combining potent cancer cell-killing agents called cytotoxic agents with cancer-targeting antibodies. The resulting ADCs are designed to selectively bind to cancer cells, delivering the cytotoxic agents directly to the cancer cells and minimizing damage to healthy cells. This targeted approach aims to improve the efficacy and safety of cancer treatments.
Immunogen has a long history of developing ADCs and its technology platform has been used to develop several clinical-stage products, including mirvetuximab soravtansine, IMGN779, IMGN632, and IMGN15 Mirvetuximab soravtansine is a promising product that targets folate receptor alpha (FRe), which is found on the surface of various types of cancer cells, including ovarian cancer. The drug has demonstrated clinical activity in patients with FRe-positive ovarian cancer and is currently in Phase 3 clinical trials.
In addition to its internal pipeline, Immunogen partners with other companies to develop ADCs using its technology. Some of its notable partnerships include collaborations with Roche, Sanofi, and Takeda.
Immunogen has a strong intellectual property portfolio, with numerous patents covering its ADC technology and processes. The company's technology and products have been recognized with numerous awards and accolades, including the Galien Foundation's Best Biotechnology Product award and the Boston Business Journal's Best Places to Work award.
Overall, Immunogen Inc. is a leader in the development of targeted cancer therapies, with a strong focus on ADCs. Its technology platform and extensive pipeline make it a promising company in the biotechnology industry.
Company Address: 830 Winter Street Waltham 2451 MA
Company Phone Number: 895-0600 Stock Exchange / Ticker: NASDAQ IMGN
|
%
1.73%